Literature DB >> 11734335

Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166.

Kouji Oba1, Hiroyuki Konno, Tatsuo Tanaka, Megumi Baba, Kinji Kamiya, Manabu Ohta, Takeshi Kaneko, Tsuyoshi Shouji, Akira Igarashi, Satoshi Nakamura.   

Abstract

MMI-166 is a selective inhibitor of matrix metalloproteinase (MMP)-2 and MMP-9. Mice implanted a human colon cancer orthotopically received 200 mg/kg of MMI-166 orally for 5 weeks. Gelatin zymography demonstrated that the administration of MMI-166 remarkably decreased the active MMP-2 expression. Histological examination revealed that MMI-166 showed prominent effect on reduction of the invasive feature of the cancer cells and showed inhibitory effect on tumor vasculature, resulting in the significant decrease of microvessel density of the implanted tumor and liver metastasis compared with the control group. Conclusively, MMI-166 is a potent antiangiogenic oral agent for a human colon cancer.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11734335     DOI： 10.1016/s0304-3835(01)00726-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  9 in total

1.  Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.

Authors:  K A Paschos; D Canovas; N C Bird
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

2.  Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid.

Authors:  K Birkenkamp-Demtroder; S H Olesen; F B Sørensen; S Laurberg; P Laiho; L A Aaltonen; T F Orntoft
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice.

Authors:  Shin-ichiro Matsumura; Shiro Iwanaga; Satsuki Mochizuki; Hiroyuki Okamoto; Satoshi Ogawa; Yasunori Okada
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  MMI-166, a selective matrix metalloproteinase inhibitor, promotes apoptosis in human pancreatic cancer.

Authors:  Chong-Chong Gao; Ben-Gang Gong; Jun-Ben Wu; Pi-Guang Cheng; Huai-Yong Xu; De-Kun Song; Fei Li
Journal:  Med Oncol       Date:  2014-12-04       Impact factor: 3.064

Review 5.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

6.  Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.

Authors:  Hiromichi Nakabayashi; Toshio Yawata; Keiji Shimizu
Journal:  BMC Cancer       Date:  2010-06-29       Impact factor: 4.430

7.  Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.

Authors:  Tanja Schneider; Franz Osl; Thomas Friess; Hubertus Stockinger; Werner V Scheuer
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 8.  Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer.

Authors:  Wubin Zheng; Fan Wu; Kai Fu; Guangshun Sun; Guoqiang Sun; Xiao Li; Wei Jiang; Hongyong Cao; Hanjin Wang; Weiwei Tang
Journal:  Onco Targets Ther       Date:  2021-05-06       Impact factor: 4.147

Review 9.  Clinical implications of angiogenesis in cancers.

Authors:  Roberta W C Pang; Ronnie T P Poon
Journal:  Vasc Health Risk Manag       Date:  2006
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.